

1 **Predictors of advanced-stage presentation among breast and cervical cancer patients in**  
2 **Ethiopia**

3

4 Birtukan Shewarega<sup>1,3</sup>, Sefonias Getachew<sup>2,3,5</sup>, Nigussie Assefa<sup>2</sup>, Abdu Adem Yesufe<sup>4</sup>, Josephin  
5 Trabizsch<sup>3,6</sup>, Yonas Dandena<sup>4</sup> Biruck Gashawubeza<sup>4</sup>, Adamu Addissie<sup>2,3,5</sup>, Eva Johanna  
6 Kantelhardt<sup>3,6</sup>, Muluken Gizaw<sup>2,3,5</sup>

7

8 **Author Affiliations**

9 <sup>1</sup>Department of Public Health Emergency Management, Woreda 12 Health Center, Yeka sub city,  
10 Addis Ababa, Ethiopia

11 <sup>2</sup>Department of Preventive Medicine, School of Public Health, Addis Ababa University, Addis  
12 Ababa, Ethiopia

13 <sup>3</sup>Global Health Working Group, Martin-Luther-University Halle-Wittenberg, Germany

14 <sup>4</sup>St. Paul's Hospital Millennium Medical College, School of Medicine, Addis Ababa, Ethiopia

15 <sup>5</sup>NCD Working Group, School Of Public Health, Addis Ababa University

16 <sup>6</sup>Department of Gynaecology, Martin-Luther-University, Halle-Wittenberg, Germany

17 Corresponding author information:

18 Name: Muluken Gizaw

19 Address: Addis Ababa, Ethiopia

20 Tele: +251966809345

21 Email: [muluken.gizaw@aau.edu.et](mailto:muluken.gizaw@aau.edu.et)

22

23

24

## 25 **Abstract**

26 Breast and cervical cancers are the most common causes of cancer incidence and mortality in  
27 women in Africa. Women with breast and cervical cancers in Sub-Saharan Africa (SSA) are  
28 frequently diagnosed at advanced stages. Delays in health seeking, diagnosis and treatment are  
29 contributing factors to high mortality in Ethiopia. This study aimed to assess predictors of  
30 advanced stage presentation among breast and cervical cancer patients attending public  
31 hospitals in Addis Ababa, Ethiopia. A cross-sectional study was conducted with a total of 418  
32 patients at Tikur Anbessa specialized hospital and Saint Pauls' Hospital Millennium Medical  
33 College from October to November 2021. Stages III and IV were considered advanced stages.  
34 Data were collected by reviewing medical records and in face-to-face interviews with a structured  
35 questionnaire. Bivariate and multivariate analyses were performed to examine the association  
36 between independent and outcome variables. A total of 269 patients with breast cancer and 149  
37 patients with cervical cancer were included in the study, and the mean age was 44 years (SD =  
38 10.9 years) and 50 years (SD = 11.2) years, respectively. About 66.9% of breast cancers and  
39 71.1% of cervical cancers were diagnosed at an advanced disease stage. Rural residence (AOR  
40 = 2.041, 95% CI: 1.108–3.758), indirect referral (AOR = 3.8, 95% CI: 1.485–9.946), financial  
41 difficulty (AOR = 10, 95% CI: 1.859–56.495) and no prior advise/awareness about screening  
42 (AOR = 4.029 95%CI: 1.658–10.102) were independent predictors of advanced-stage  
43 presentation. This study revealed a high prevalence of advanced-stage breast and cervical cancer  
44 diagnosis in Ethiopia, similar to data collected 10 years ago, despite the introduction of a cancer  
45 control plan in 2015. For better implementation, interventions should aim to improve referral  
46 pathways, adapt screening and early detection services and increase cancer awareness at the  
47 community level in a culturally accepted way.

48 **Keywords:** breast cancer, cervical cancer, advanced-stage presentation, predictors, Ethiopia

49

## 50 **Background**

51 Breast and cervical cancers are the most commonly diagnosed cancers in women worldwide [1].  
52 Women from Sub-Saharan Africa are disproportionately affected by both cancers, which contribute  
53 to the high burden of mortality in this region [2]. Both cancers are responsible for 50% of the  
54 cancer burden in women in Ethiopia [2]. Women with breast and cervical cancers in Sub-Saharan  
55 Africa (SSA) are frequently diagnosed at an advanced stage [3-5].

56 The five-year survival of cervical cancer in SSA is less than 50%, and an advanced stage at  
57 diagnosis and late initiation of treatment are the two outstanding contributing factors to poor  
58 survival in this region [6]. Breast cancer patients also present at an advanced stage due to the  
59 longer patient interval and lack of access to health facilities with diagnostic capacity in the patient's  
60 vicinity [7]. Moreover, complicated referrals and longer diagnostic intervals have contributed to  
61 the delay in diagnosis and initiation of curative treatment [4].

62 Delays in referring these patients to the higher level are one of the contributing factors to late  
63 diagnosis and poor survival in SSA, including Ethiopia [8]. Lack of health infrastructure, a large  
64 patient flow in the hospital, long diagnostic intervals and patients' repeated visits to different health  
65 facilities for diagnosis and treatment have been identified as contributing factors to late-stage  
66 diagnosis and poor survival in SSA [9-13].

67 However, despite a robust search of previous studies, we could not determine how delayed  
68 referral of those patients to secondary care is associated with advanced stage among both breast  
69 and cervical cancer patients in two public oncology centres in Addis Ababa, Ethiopia. Therefore,  
70 the present study explains the association between the direct referral path and advanced-stage  
71 presentation. We also sought to identify common individuals, health systems and clinical factors  
72 contributing to late-stage diagnosis among breast and cervical cancer patients diagnosed at a  
73 late stage.

## 74 **Methods**

75 **Study design and Setting:** An institutional based, cross-sectional study was conducted in Tikur  
76 Anbessa specialized hospital (TASH) and Saint Pauls' Hospital Millennium Medical College  
77 (SPHMMC), two public referral hospitals (TASH and SPHMMC) in Addis Ababa. Tikur Anbessa  
78 Specialized Hospital is the largest cancer treatment centre including radiation treatment. St.  
79 Paul's Hospital Millennium Medical College is the second referral and teaching hospital offering  
80 cancer treatment following TASH.

81 **Study participants:** A total of 418 histopathologically confirmed breast and cervical cancer (aged  
82 >18 years) patients who were diagnosed at least 1 month prior to the data collection period and  
83 on follow up for treatment were enrolled in the study. Those breast and cervical cancer patients  
84 who were critically ill or missing dates regarding pathological diagnosis, cancer staging and  
85 symptom onset were excluded from the study.

## 86 **Sampling technique and sample size**

87 The hospitals were selected purposively by the criteria of having oncology services. Consecutive  
88 sampling was used to enrol study subjects. The sample size was calculated using the single  
89 population proportion formula with Epi info version 4.1 software using the parameters 95%  
90 confidence interval, 80% power, 5% margin of error and proportion advanced-stage presentation  
91 of cervical cancer patient study conducted at TASH  $p = 55.2\%$  [14].

## 92 **Variables and measurements**

93 The following Aarhus statement criteria were used for classifying patient and diagnostic  
94 intervals:

95 The **patient interval/appraisal interval** was defined as the time interval from first symptom  
96 recognition (the time point when first bodily changes and/or symptoms were noticed) to

97 presentation to the first health care provider, and a **patient appraisal /patient delay** was defined  
98 as a patient interval greater than three months (> 90-day)[15].

99 The **diagnostic interval** was defined as the interval from the date of first clinical presentation to  
100 the date of pathological diagnosis. The date of diagnosis was taken from the patient's pathology  
101 report. A **diagnostic delay** was defined as a time interval between the first clinical presentation  
102 and the date of pathological diagnosis (diagnostic interval) greater than 30 days [4].

103 **Direct referral** occurred when patients with a given set of symptoms were referred within two  
104 weeks and obtained a diagnosis of cancer within two weeks in the first receiving facility [16].

105 **Financial difficulty** was defined as financial hardship incurred for transportation and medical  
106 expenses.

#### 107 **Data collection and data quality assurance**

108 Data were collected by a review of medical records and face-to-face interviews using structured  
109 questionnaires. Nurses who were working in the oncology department collected data, and training  
110 was offered for three days. Pretesting was performed prior to data collection in 20 respondents.

#### 111 **Data analysis**

112 Descriptive statistics were used to measure the frequency and proportion of advanced disease  
113 presentation. Bivariate and multivariable logistic regression analyses were used to identify  
114 predictors of advanced stage diagnosis.

#### 115 **Ethical consideration**

116 Ethical clearance was secured from the Institutional Review Board of the School of Public Health,  
117 College of Health Science, and Addis Ababa University (SPH/1119/2021). Verbal consent was  
118 obtained from all study participants. The confidentiality of participants was kept by not sharing  
119 their personal identifiers in all research processes.

120

121 **Result**

122 **Socio-demographic characteristics of the respondents**

123 The mean age was 44 years (SD = 10.9 years) and 50 years (SD = 11.2) for breast cancer and  
124 cervical cancer, respectively. Around 234 (56%) of the study participants were from urban areas,  
125 while 44% were rural dwellers. A quarter (106; 25.4%) of participants could not read or write, and  
126 185 (44.2%) had attended secondary school or above. Around 267 (63.9%) respondents were  
127 married and 310 (74.2%) were Orthodox Christian by religion.

128 **Table 1. Socio-demographic characteristics of respondents in TASH and SPHMMC, 2021**

Variable	Category	Frequency (n = 418)	Percent (%)
Age	≤50	272	65.1
	≥51	146	34.9
Religion	Orthodox	310	74.2
	Muslim	63	15.1
	protestant	45	10.8
Residence	Urban	234	56.0
	Rural	184	44.0
Educational	Cannot read and write	106	25.4
	Can read and write	38	9.1
	Elementary	89	21.3
	Secondary and above	185	44.2
Marital status	Married	267	63.9
	Single	19	4.5

	Divorced	70	16.7
	widowed	62	14.8
Occupation	Housewife	217	51.9
	Government employee	80	19.1
	Private employee	39	9.3
	Merchant	13	3.1
	Daily labourer	12	2.9
	Student	2	.5
	Retired	9	2.2
	Farmer	46	11.0

129

130 Close to half (132; 49.07%) of breast cancer patients  $\leq 50$  years of age had advanced-stage  
 131 presentation, whereas only 48 (17.84%) respondents in the  $>50$  age group had advanced-stage  
 132 presentation. However, there was an equal proportion of cervical cancer patients with advanced-  
 133 stage presentation, 53 (35.57%), in both age groups.

134 Around 36.43% of breast cancer and 34.23% of cervical cancer patients had a monthly income  
 135 of less than 5000 ETB.

136 **Table 2. Socio-demographic characteristics of participants according to disease**  
 137 **presentation at diagnosis in TASH and SPHMMC, 2021**

Variable	Category	Early Breast Cancer	Late Breast Cancer	Early Cervical Cancer (Frequency [%])	Late Cervical Cancer (Frequency [%])
----------	----------	---------------------	--------------------	---------------------------------------	--------------------------------------

		(Frequency [%])			
Age	≤50	62(23.04%)	132(49.07%)	25(16.78%)	53(35.57%)
	>50	27(10.03%)	48(17.84%)	18(12.08%)	53(35.57%)
Religion	Orthodox	62(23.04%)	134(49.82%)	31(20.51%)	83(55.70%)
	Muslim	18(6.69%)	25(9.29%)	8(5.37%)	12(8.05%)
	protestant	9(3.35%)	21(7.81%)	4(2.68%)	11(7.38)
Residence	Urban	65(24.16%)	101(37.55%)	29(19.46%)	39(26.17%)
	Rural	24(8.92%)	79(29.37%)	14(9.40%)	67(44.97%)
Educational	Can't read and write	44(16.36%)	94(34.94%)	12(8.05%)	47(31.54%)
	Can read and write	21(7.81%)	44(16.36%)	5(3.36%)	14(9.40%)
	Elementary	10(3.72%)	17(6.32%)	8(5.37%)	21(14.09%)
	Secondary and above	14(5.2%)	25(9.29%)	18(12.08%)	24(16.11%)
Marital status	Married	55(20.45%)	110(40.89%)	31(20.81%)	71(47.65%)
	Single	4(1.49%)	11(4.09%)	0(0%)	4(2.38%)
	Divorced	16(5.95%)	32(11.89%)	6(4.02%)	16(10.74%)
	widowed	14(5.2%)	27(10.04%)	6(4.02%)	15(10.07%)
	Occupation	Housewife	44(16.36%)	94(34.94)	23(15.44%)
	Government employee	21(7.81%)	44(16.36%)	7(4.69%)	8(5.37%)
	Private	10(3.72%)	17(6.32%)	3(2.02%)	9(6.04%)



---

	employee				
	Merchant	2(0.7%)	8(2.974%)	0(0%)	3(2.02%)
	Daily labourer	3(1.12%)	3(1.12%)	2(1.34%)	4(2.68%)
	Student	1(0.4%)	1(0.4%)	2(1.34%)	2(1.34%)
	Retired	3(1.12%)	2(0.7%)	6(4.03%)	24(16.11%)
	Farmer	5(1.86%)	11(4.09%)	23(15.44%)	56(37.58%)
Monthly income	≤5000	53(19.7)	98(36.43%)	23(15.44%)	51(18.95%)
	>5000	36(13.38%)	82(30.48%)	20(13.42%)	55(36.91%)

---

138

139 **Clinical characteristics of respondents**

140 About half (51.3%) and 71 (47.7%) breast cancer and cervical cancer patients were on  
 141 chemotherapy alone, respectively. About 38.3% of cervical cancer patients took chemotherapy  
 142 and radiation therapy. The majority of breast cancer patients (66.9%) were diagnosed at an  
 143 advanced disease stage (III & IV). Similarly, 71.1% of cervical cancer patients were in an  
 144 advanced stage. Screening awareness was present in 108 (40.1 %) and 43 (29.8%) breast and  
 145 cervical cancer patients, respectively. Among them, only 0.4% of breast and 6% of cervical cancer  
 146 patients had a history of screening practice before diagnosis. Almost 85% of breast cancer  
 147 patients had complained of a breast lump at presentation. Similarly, 92 (62.2%) cervical cancer  
 148 patients had a presenting complaint of bloody vaginal discharge followed by pelvic pain (22.3%)  
 149 or non-bloody vaginal discharge (10.8%).

150

151

152

153

154 **Table 3. Clinical characteristics of respondents in TASH and SPHMMC, Addis Ababa,**  
 155 **Ethiopia 2021**

Variable	Category	Frequency (n = 418)	Percent (%)	Breast cancer (n = 269)(%)	Cervical cancer (n = 149) & (%)
Cancer stage	Stage I	27	6.5	17(6.3)	10(6.7)
	Stage II	109	26.1	73(27.1)	36(24.2)
	Stage III	166	39.7	112(41.6)	54(36.2)
	Stage IV	116	27.8	67(24.9)	49(32.9)
Type of diagnosis	FNA	84	20.1	83(30.9)	0(0)
	biopsy	175	41.9	174(64.7)	0(0)
	Punch biopsy	147	35.2	0(0)	149(100)
Type of treatment	Surgical incision	12	2.9	12(4.5)	0(0)
	Surgery	57	13.6	47(17.5)	10(6.7)
	Chemotherapy	209	50.0	138(51.3)	71(47.7)
	Neoadjuvant chemotherapy	24	5.7	19(7.1)	5(3.4)
	Radiotherapy	9	2.2	3(1.1)	6(4.0)

	Chemotherapy and radiotherapy	115	27.5	58(21.6)	57(38.3)
	Hormonal therapy	4	1.0	4(21.6)	0(0)
Screening awareness	Yes	151	36.1	108(40.1)	43(28.9)
	No	267	63.9	161(59.9)	106(71.1)
Screening/Early Detection practice	Yes	10	2.4	1(0.4)	9(6%)
	No	408	97.6	268(99.6)	140(94%)

156

157 **Predictors of advanced-stage presentation among breast and cervical cancer patients**

158 Breast and cervical cancer patients who had been referred indirectly were more likely to present  
 159 at an advanced disease stage than those who had been referred directly (AOR of 3.843; 95%CI  
 160 = 1.485–9.946). Similarly, rural residents were 2 times more likely to be diagnosed at an advanced  
 161 disease stages than those who lived in urban areas (AOR of 2.041; 95%CI = 1.108–3.758). Breast  
 162 and cervical cancer patients who had a patient delay >3 months were 2.5 times more likely to  
 163 have advanced-stage presentation than their counterparts (AOR = 2.479; 95% CI = 1.078–5.704).  
 164 Moreover, breast and cervical cancer patients who reported financial difficulties were more likely  
 165 to have advanced-stage presentation than their counterparts (AOR = 10.102; 95% CI = 1.658–  
 166 10.248). A substantial percentage, 73.7%(308) of breast and cervical cancer patients were  
 167 unaware of the symptoms before being diagnosed, causing the patient to appear late for  
 168 diagnosis and treatment. Those women who had low awareness about screening and disease  
 169 itself were approximately 4 times more likely to have advanced-stage presentation than who had

170 higher awareness (AOR = 4.092; 95% CI = 1.078–5.704). Our findings show that 45.3% of  
171 participants had a delay in diagnosis following the initial medical consultation. The health system  
172 (delayed referral and waiting test results) or the health care provider (misdiagnosis) were  
173 responsible for the delay in diagnosis.

174

175 **Table 4. Factors associated with advanced-stage presentation among breast/cervical**  
176 **cancer patients in TASH and SPHMMC Addis Ababa, Ethiopia, 2021**

---

Variable	Category	COR with 95% CI	AOR with 95% CI
Referral status	direct	1.0	1.0
	indirect	18.079 (10.652-30.683)	3.843 (1.485-9.946)
Financial difficulties reported	No	1.0	1.0
	Yes	4.887 (1.125-21.226)	10.248 (1.859-56.495)
Awareness level	Lower	1.0	1.0
	Higher	17.836 (9.569-33.244)	4.092 (1.658-10.102)
Patient delay >3 months	No	1.0	1.0
	Yes	2.943 (1.697-5.101)	2.479 (1.078-5.704)
Residence	Urban	1.0	1.0
	Rural	2.580 (1.657-4.015)	2.041 (1.108-3.758)

---

177 *\*Only variables with P < 0.25 were included in the multivariable analysis*

178

179

180

181

## 182 **Discussion**

183 This study examined the predictors of advanced-stage presentation among breast and cervical  
184 cancer patients in Ethiopia. About two thirds of breast and cervical cancer patients were  
185 diagnosed at an advanced disease stage. An indirect referral path, financial difficulty, rural  
186 residence, a low awareness level and a patient delay >3 months were independent predictors of  
187 advanced-stage presentation.

188 The findings of such high proportions of advanced breast cancer disease at diagnosis were  
189 consistent with those of north-east Ethiopian (65.7%), Nigerian (67.7%) and Indian studies (68%)  
190 [12,17,18]. However, they were lower than those reported in a study conducted in north-west  
191 Ethiopia (71.2%)[3] and higher than those of studies conducted in South Africa (51%), Pakistan  
192 (59%) and Germany (51.6%)[19-21]. The proportion of cervical cancer patients with an advanced  
193 stage of disease was nearly similar to those in studies conducted in Nigeria (72.8%)[15] and  
194 Sudan (72%)[22] and higher than that in a study conducted in TASH in 2021, which was  
195 (56.8%)[23], and a population-based cross-sectional study conducted in Addis Ababa  
196 (60.4%)[24].

197 According to the findings, a large proportion of women with breast and cervical cancer were  
198 unaware of the symptoms prior to their diagnosis, resulting in a delay in patient presentation for  
199 diagnosis and treatment. The proportion of patients who were delayed accounts for 73.7% (308),  
200 which is higher than that in studies conducted at Dessie Referral Hospital, north-east Ethiopia's  
201 only oncology unit 50.5% [25] and northern India 65.3%[12]. Another study from Ethiopia at TASH  
202 in 2010 showed that almost half of the study participants (n = 33; 47.8%) said that women in  
203 Ethiopia typically know nothing about breast cancer and, in fact, have often never heard of the

204 disease at all. This difference might be due to the difference in sample size of the studies, adoption  
205 of different cut-off points for classifying patient delay and a difference in study populations [26].

206 Our study showed the effects of a patient delay of >3 months on advanced-stage diagnosis of  
207 breast and cervical cancer patients. The longer the patient delay time, the more likely the patient  
208 was diagnosed at an advanced disease stages. Patients who had a presentation delay of >3  
209 months were 2.4 times more likely to be diagnosed at an advanced stage than those who had no  
210 patient delay. Disease progression is expected during a delay. A similar finding was reported in  
211 studies conducted in north-east Ethiopia, in which 50.5% (103) women with breast cancer were  
212 delayed for >3 months. Out of these delayed women, 75 (72.8%) were diagnosed at a late stage  
213 ( $p < 0.030$ ) [25]. Similarly, a longer patient interval in patients with cervical cancer is associated  
214 with more advanced FIGO stages at diagnosis, according to a study performed at TASH [14].

215 According to our findings, the delay in diagnosis after the initial medical consultation was  
216 attributed to either the health system (delayed referral and waiting test result) or the health care  
217 provider (misdiagnosis), in 45.3% of cases. A similar result was reported from Egypt (37%) [27].

218 The study revealed that the odds of advanced-stage presentation were 2.0 times greater in  
219 patients residing in rural than in urban areas. This finding is nearly identical to that of a 2021 study  
220 in TASH [23] and similar to those of studies conducted in Sudan [22], Nigeria [17] and north-west  
221 Ethiopia [3]. This is probably because women who live in places with limited access to health care  
222 or who travel longer distances for treatment are more likely experience a delay. Additionally,  
223 cancer literacy is probably lower in rural settings. However, this finding contrasts with those of a  
224 study on cervical cancer patients conducted in 2019 at TASH Ethiopia [14], which found that the  
225 place of residency was not a predictor of advanced-stage disease presentation. This discrepancy  
226 could be explained by differences in study methods, settings, sample sizes and research  
227 participants.

228 Our study found no evidence of associations between level of education, age or marital status  
229 and advanced-stage presentation. This finding is supported by previous studies in Ethiopia and  
230 Nigeria, where age was not associated with an advanced disease stage [14,27]. Nonetheless,  
231 this result is in contrast with another studies in Nigeria and Ethiopia, which reported that age and  
232 level of education were strong determinants of stage at diagnosis in cervical cancer [23,27].  
233 Women without a high school diploma and those who were above the age of 60 had a  
234 considerably higher risk of developing advanced-stage disease than their counterparts [23,27,28].  
235 This disparity could be related to differences in the study location and participants.

236 Consistent with findings from prior studies [16,19], indirect referral significantly affected advanced-  
237 stage presentation in the current study. The odds of advanced-stage presentation were higher  
238 among women with breast and cervical cancer patients who were referred indirectly (AOR 3.843,  
239 95% CI (1.485–9.946)); this probably reflects the longer duration of referral.

240 Our study has some limitations. First, even though this study involved a relatively large sample  
241 size, due to the nature of a cross-sectional study, the establishment of a causal relationship was  
242 not possible. Second, the retrospective nature of information collection from patients on the dates  
243 of symptom recognition and medical consultations is prone to recall bias and could have affected  
244 the measurement of intervals and other variables, but we have tried to minimize it by using  
245 standard tools, carefully designing the questionnaire and training the data collectors.

## 246 **Conclusion**

247 Despite the efforts made by the government to improve cancer care and patient outcomes, the  
248 majority of breast and cervical cancer patients present at an advanced disease stage. Shortening  
249 the referral pathways and designing a direct 'fast track' referral for diagnosis and treatment could  
250 help to improve the delay in diagnosis and treatment initiation. Implementing diagnostic walk-in  
251 centres could be an option to achieve this. Awareness-raising activities should target the general

252 population to promote screening for both cancers and facilitate early detection. Special attention  
253 must be given to vulnerable segments of the population, such as rural residents and women with  
254 low incomes.

## 255 **Abbreviations**

256 AAU: Addis Ababa University, TASH: Tikur Anbessa Specialized Hospital, SPHMMC: St. Paul's  
257 Hospital Millennium Medical College, SPSS: Statistical Package for The Social Sciences, AOR:  
258 adjusted odds ratio, CI: confidence interval, SD: standard deviation HCP: healthcare providers,  
259 VIF: variance inflation factor, ETB: Ethiopian birr

## 260 **Author Contributions**

261 **Conceptualization:** Birtukan Shewarega, Muluken Gizaw, Nigussie Assefa, Sefonias Getachew,  
262 Adamu Addissie, Eva Johanna Kantelhardt, Josephin Trabizsch

263 **Formal analysis:** Birtukan Shewarega,

264 **Funding acquisition:** Adamu Addissie, Eva Johanna Kantelhardt

265 **Investigation:** Birtukan Shewarega

266 **Methodology:** Birtukan Shewarega, Muluken Gizaw, Nigussie Assefa, Sefonias Getachew,  
267 Adamu Addissie, Eva Johanna Kantelhardt, Josephin Trabizsch, Abdu Adem Yesufe, Yonas  
268 Dandena, Biruck Gashawubeza

269 **Project administration:** Adamu Addissie, Eva Johanna Kantelhardt

270 **Supervision:** Muluken Gizaw, Nigussie Assefa, Abdu Adem Yesufe, Yonas Dandena, Biruck  
271 Gashawubeza

272 **Visualization:** Birtukan Shewarega

273 **Writing – original draft:** Birtukan Shewarega,



274 **Writing – review & editing, final approval of the manuscript:** Birtukan Shewarega, Muluken  
275 Gizaw, Nigussie Assefa, Sefonias Getachew, Adamu Addissie, Eva Johanna Kantelhardt,  
276 Josephin Trabizsch, Abdu Adem Yesufe. Yonas Dandena, Biruck Gashawubeza

## 277 **Acknowledgements**

278 The authors would like to thank Tigist Birie and Sosina Kassa for their support during data  
279 collection.

## 280 **References**

- 281 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer  
282 statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185  
283 countries. *CA Cancer J Clin.* 2021;71(3):209-249
- 284 2. WHO, IARC. Global cancer observatory: Cancer today. 2020. Available from URL:  
285 <https://gco.iarc.fr/today/home>
- 286 3. Tesfaw A, Tiruneh M, Tamire T, Yosef T. Factors associated with advanced-stage  
287 diagnosis of breast cancer in north-west Ethiopia: a cross-sectional study.  
288 *Ecancermedicalscience.* 2021;15.
- 289 4. Gebremariam A, Addissie A, Worku A, Assefa M, Pace LE, Kantelhardt EJ, et al. Time  
290 intervals experienced between first symptom recognition and pathologic diagnosis of breast  
291 cancer in Addis Ababa, Ethiopia: a cross-sectional study. *BMJ open.* 2019;9(11).
- 292 5. Sengayi-Muchengeti M, Joko-Fru WY, Miranda-Filho A, Egue M, Akele-Akpo MT, N'da G,  
293 et al. Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human  
294 Development Index: A population-based registry study. *Int J Cancer.* 2020;147(11):3037-48.

- 295 6. Zeleke S, Anley M, Kefale D, Wassihun B. Factors associated with delayed diagnosis of  
296 cervical cancer in tikur anbesa specialized hospital, Ethiopia, 2019: Cross-Sectional Study.  
297 Cancer Manag Res. 2021;13:579.
- 298 7. Duche H, Tsegay AT, Tamirat KS. Identifying risk factors of breast cancer among women  
299 attending selected hospitals of Addis Ababa city: Hospital-based unmatched case-control study.  
300 Breast Cancer: Targets and Therapy. 2021;13:189.
- 301 8. Majeed I, Ammanuallah R, Anwar AW, Rafique HM, Imran FJEMHJ. Diagnostic and  
302 treatment delays in breast cancer in association with multiple factors in Pakistan. Eastern  
303 Mediterranean Health Journal. 2020;26.
- 304 9. Pierz AJ, Randall TC, Castle PE, Adedimeji A, Ingabire C, Kubwimana G, et al. A scoping  
305 review: Facilitators and barriers of cervical cancer screening and early diagnosis of breast cancer  
306 in Sub-Saharan African health settings. Gynecology oncology report. 2020:100605.
- 307 10. Sardi A, Orozco-Urdaneta M, Velez-Mejia C, Perez-Bustos AH, Munoz-Zuluaga C, El-  
308 Sharkawy F, et al. Overcoming barriers in the implementation of programs for breast and cervical  
309 cancers in Cali, Colombia: a pilot model. J Glob Oncol. 2019;5:1-9.
- 310 11. Pearson C, Poirier V, Fitzgerald K, Rubin G, Hamilton WJBo. Cross-sectional study using  
311 primary care and cancer registration data to investigate patients with cancer presenting with non-  
312 specific symptoms. BMJ open. 2020;10(1).
- 313 12. Shreyamsa M, Singh D, Ramakant P, Anand A, Singh KR, Mouli S, et al. Barriers to Timely  
314 Diagnosis and Management of Breast Cancer: Observations from a Tertiary Referral Center in  
315 Resource Poor Setting. Indian J Surg Oncol. 2020;11(2):287.
- 316 13. Dobson CM, Russell AJ, Rubin GPJBhsr. Patient delay in cancer diagnosis: what do we  
317 really mean and can we be more specific? BMC health services research. 2014;14(1):1-6.

- 318 14. Begoihn M, Mathewos A, Aynalem A, Wondemagegnehu T, Moelle U, Gizaw M, et al.  
319 Cervical cancer in Ethiopia—predictors of advanced stage and prolonged time to diagnosis. *Infect*  
320 *Agent Cancer*. 2019;14(1):36.
- 321 15. Awofeso O, Roberts AA, Salako O, Balogun L, Okediji P. Prevalence and pattern of late-  
322 stage presentation in women with breast and cervical cancers in Lagos University Teaching  
323 Hospital, Nigeria. *Nigerian Medical Journal: J Nigeria Medical Association*. 2018;59(6):74.
- 324 16. Pothas C, Nietz S, Oluwa T, Witness M, Cubasch H, Joffe M. Time to first health care  
325 contact, referral pathways and stage at presentation—the experience from four South African  
326 breast units. *Eur J Cancer*. 2020;138:S69.
- 327 17. Jedy-Agba E, McCormack V, Olaomi O, Badejo W, Yilkudi M, Yawe T, et al. Determinants  
328 of stage at diagnosis of breast cancer in Nigerian women: sociodemographic, breast cancer  
329 awareness, health care access and clinical factors. *Cancer Causes Control*. 2017;28(7):685-97.
- 330 18. Dye TD, Bogale S, Hobden C, Tilahun Y, Hechter V, Deressa T, et al. Complex care  
331 systems in developing countries: breast cancer patient navigation in Ethiopia. *Cancer*.  
332 2010;116(3):577-85.
- 333 19. Joffe M, Ayeni O, Norris SA, McCormack VA, Ruff P, Das I, et al. Barriers to early  
334 presentation of breast cancer among women in Soweto, South Africa. *PloS one*.  
335 2018;13(2):e0192071.
- 336 20. Arndt V, Stürmer T, Stegmaier C, Ziegler H, Dhom G, Brenner HJBjoc. Patient delay and  
337 stage of diagnosis among breast cancer patients in Germany—a population based study.  
338 *JournalCancer* . 2002;86(7):1034-40.

- 339 21. Gulzar F, Akhtar MS, Sadiq R, Bashir S, Jamil S, Baig SM. Identifying the reasons for  
340 delayed presentation of Pakistani breast cancer patients at a tertiary care hospital. *Cancer Man*  
341 *Res.* 2019;11:1087.
- 342 22. Ibrahim A, Rasch V, Pukkala E, Aro ARJljowsh. Predictors of cervical cancer being at an  
343 advanced stage at diagnosis in Sudan. *Int J Womens Health.* 2011;3:385.
- 344 23. Wassie M, Fentie B. Prevalence of late-stage presentation and associated factors of  
345 cervical cancer patients in Tikur Anbesa Specialized Hospital, Ethiopia: institutional based cross-  
346 sectional study. *Infect Agent Cancer.* 2021;16(1):1-6.
- 347 24. Dereje N, Gebremariam A, Addissie A, Worku A, Assefa M, Abraha A, et al. Factors  
348 associated with advanced stage at diagnosis of cervical cancer in Addis Ababa, Ethiopia: a  
349 population-based study. *BMJ open.* 2020;10(10):e040645.
- 350 25. Hassen AM, Hussien FM, Asfaw ZA, Assen HE. Factors Associated with Delay in Breast  
351 Cancer Presentation at the Only Oncology Center in North East Ethiopia: A Cross-Sectional  
352 Study. *J Multidiscip Healthc.* 2021;14:681.
- 353 26. De Ver Dye T, Bogale S, Hobden C, Tilahun Y, Hechter V, Deressa T, et al. A mixed-  
354 method assessment of beliefs and practice around breast cancer in Ethiopia: implications for  
355 public health programming and cancer control. *Glob Public Health.* 2011;6(7):719-31.
- 356 27. Abdel-Fattah MM, Anwar MA, Mari E, El-Shazly MK, Zaki AA, Bedwani RN, et al. Patient-  
357 and system-related diagnostic delay in breast cancer. *Eur J Public Health.* 1999;9(1):15-9.
- 358 28. McKenzie F, Zietsman A, Galukande M, Anele A, Adisa C, Parham G, et al. Drivers of  
359 advanced stage at breast cancer diagnosis in the multicountry African breast cancer–disparities  
360 in outcomes (ABC-DO) study. *Int J Cancer.* 2018;142(8):1568-79.

361

It is made available under a [CC-BY 4.0 International license](#) .

362

363